BioWorld

Aug. 3, 2010

Novel MicroRNA Controls Angiogenic Switch in Model

Eli Lilly CEO Provides Hints About Firm's Global Direction

Other News To Note

Stock Movers

Trius Decreases Size of IPO Deal from $78M to $49M

After delaying its initial public offering earlier this year, Trius Therapeutics Inc. said Monday that it now plans to decrease the size of its proposed IPO deal. (BioWorld Today) Read More

Waiting for Payday: Symphony Agrees to Lexicon JV Buyout

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...